P. Schroth

发表

Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients

C. Négrier, A. Shapiro, M. Tarantino, 2008, Thrombosis and Haemostasis.

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

K. Fischer, G. Spotts, V. Blanchette, 2010, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-stage Clotting and Chromogenic Factor VIII Assay

P. Giangrande, E. Gomperts, C. Hay, 1999, Thrombosis and Haemostasis.

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1

A. Shapiro, M. Tarantino, C. Hay, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

H. Ehrlich, A. Shapiro, P. Collins, 2009 .

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.

G. Spotts, V. Blanchette, K. Fischer, 2012, Blood.

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

G. Spotts, V. Blanchette, K. Fischer, 2011, Haemophilia.

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

J. Astermark, G. Spotts, V. Blanchette, 2009, Journal of thrombosis and haemostasis : JTH.

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

G. Spotts, V. Blanchette, I. Warrier, 2008, Journal of thrombosis and haemostasis : JTH.

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

L. Valentino, D. Quon, P. Schroth, 2012, Journal of thrombosis and haemostasis : JTH.

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

G. Spotts, V. Blanchette, K. Fischer, 2010, Journal of thrombosis and haemostasis : JTH.

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

J. Astermark, G. Spotts, V. Blanchette, 2007 .

Characterization of the Pharmacokinetics of rFVIII in Young Pre-School Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight.

G. Spotts, V. Blanchette, A. Shapiro, 2004 .

Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring

G. Spotts, V. Blanchette, K. Fischer, 2010 .

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

G. Spotts, V. Blanchette, K. Fischer, 2008 .

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.

H. Ehrlich, A. Shapiro, P. Collins, 2009, Expert opinion on biological therapy.

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

G. Spotts, V. Blanchette, K. Fischer, 2009 .

ERROR IN BLOOD-PRESSURE MEASUREMENT DUE TO INCORRECT CUFF SIZE IN OBESE PATIENTS

P. Schroth, L. Dornfeld, M. Karam, 1982, The Lancet.

Maternal Serum a-Fetoprotein Screening for the Detection of Neural Tube Defects Report of a Pilot Program

B. Crandall, P. Schroth, W. King, 2022 .

1-C-glucuronidation of N-nitrosodiethylamine and N-nitrosomethyl-n-pentylamine in vivo and in primary hepatocytes from rats pretreated with inducers.

E. Frei, K. Wiench, P. Schroth, 1992, Carcinogenesis.

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

J. Astermark, V. Blanchette, P. Collins, 2006 .

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

J. Astermark, G. Spotts, V. Blanchette, 2009, Journal of thrombosis and haemostasis : JTH.